Satralizumab : an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders
Copyright 2021 Clarivate Analytics..
Neuromyelitis optica spectrum disorders (NMOSD) consist of a rare autoimmune disorder in which patients suffer from relapses that affect the optic nerve, spinal cord or brainstem. Few have a full recovery. NMOSD is more common in women, the age of onset being around 30-40 years of age depending on race. The prevalence of the condition varies from 0.5-4.4 per 100,000 population. About 80% of patients have antibodies directed against the aquaporin-4 (AQP4) protein that form membrane-bound water transporters in the central nervous system (CNS). This protein is highly expressed in those areas of the CNS often targeted in NMOSD relapses. Satralizumab is a humanized monoclonal antibody that binds to the interleukin-6 (IL-6) receptor and thus inhibits IL-6 signaling. Two recent phase III studies have demonstrated that satralizumab significantly reduced the relapse rate in NMOSD by 76-79%. This beneficial effect was apparently confined to patients who have anti-AQP4 antibodies and satralizumab did not reduce the rate of pain or fatigue in NMOSD patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:57 |
|---|---|
| Enthalten in: |
Drugs of today (Barcelona, Spain : 1998) - 57(2021), 3 vom: 01. März, Seite 209-218 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Paton, D M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.03.2021 Date Revised 19.03.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1358/dot.2021.57.3.3251715 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322858410 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322858410 | ||
| 003 | DE-627 | ||
| 005 | 20231225182931.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1358/dot.2021.57.3.3251715 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1076.xml |
| 035 | |a (DE-627)NLM322858410 | ||
| 035 | |a (NLM)33729218 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Paton, D M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Satralizumab |b an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.03.2021 | ||
| 500 | |a Date Revised 19.03.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2021 Clarivate Analytics. | ||
| 520 | |a Neuromyelitis optica spectrum disorders (NMOSD) consist of a rare autoimmune disorder in which patients suffer from relapses that affect the optic nerve, spinal cord or brainstem. Few have a full recovery. NMOSD is more common in women, the age of onset being around 30-40 years of age depending on race. The prevalence of the condition varies from 0.5-4.4 per 100,000 population. About 80% of patients have antibodies directed against the aquaporin-4 (AQP4) protein that form membrane-bound water transporters in the central nervous system (CNS). This protein is highly expressed in those areas of the CNS often targeted in NMOSD relapses. Satralizumab is a humanized monoclonal antibody that binds to the interleukin-6 (IL-6) receptor and thus inhibits IL-6 signaling. Two recent phase III studies have demonstrated that satralizumab significantly reduced the relapse rate in NMOSD by 76-79%. This beneficial effect was apparently confined to patients who have anti-AQP4 antibodies and satralizumab did not reduce the rate of pain or fatigue in NMOSD patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Interleukin-6 (IL-6) receptor antagonists | |
| 650 | 4 | |a Monoclonal antibodies | |
| 650 | 4 | |a Neurological disorders | |
| 650 | 4 | |a Neuromyelitis optica spectrum disorders | |
| 650 | 4 | |a Satralizumab | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Aquaporin 4 |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a satralizumab |2 NLM | |
| 650 | 7 | |a YB18NF020M |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs of today (Barcelona, Spain : 1998) |d 1998 |g 57(2021), 3 vom: 01. März, Seite 209-218 |w (DE-627)NLM123139600 |x 1699-3993 |7 nnns |
| 773 | 1 | 8 | |g volume:57 |g year:2021 |g number:3 |g day:01 |g month:03 |g pages:209-218 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1358/dot.2021.57.3.3251715 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 57 |j 2021 |e 3 |b 01 |c 03 |h 209-218 | ||